Adoptive immunotherapy using spleen cells activated with Iscador was found
to inhibit tumour growth significantly (P<0.001). Metastatic B16F10 tumour
bearing animals treated with a single dose of spleen cells activated with I
scador (in vitro) showed 100% inhibition of tumour nodule formation on 21st
day. Single injection of splenocytes isolated from mice treated with Iscad
or inhibited the tumour nodule formation by 93.8%. Animals treated with in
vivo and in vitro activated spleen cells along with Iscador had an increase
in life span of 119% and 81% respectively. Treatment of animals with low d
ose of Iscador after adoptive immunotherapy further augmented the life span
. Animals which underwent adoptive immunotherapy showed significantly reduc
ed lung collagen hydroxyproline (9.8 mu g/mg protein) and serum sialic acid
(24.6 mu g/ml serum)levels compared to control tumour bearing animals with
increased levels of lung hydroxyproline (26.95 mu g/mg protein) and serum
sialic acid levels (151.3 mu g/ml serum). Serum gamma -glutamyl transpeptid
ase levels were found to be significantly reduced in the group of animals t
reated with Iscador and Iscador activated splenocytes (16.6 +/- 2.3 nmol P-
nitroaniline released /ml serum). Group of animals treated with Iscador act
ivated splenocytes alone also showed significantly reduced serum gamma - gl
utamyl transpeptidase levels (17.3 +/- 10 nmol P-nitroaniline released /ml
serum) compared to control tumour bearing animals (91 +/- 12 nmol P-nitroan
iline released /ml serum).